用包括PD-1抑制剂在内的组合治疗转移性黑色素瘤的管理

Lara Valeska Maul1,2, Egle Ramelyte1,2, Reinhard Dummer1,2

  • 1Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

概括

免疫检查点抑制剂 (ICI) 已经改变了转移性黑色素瘤的治疗方法,为许多人提供了持久的控制. 组合有希望,但增加不良事件,需要生物标志物研究以进行个性化治疗.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...